States to Seek Direct Appeal of Purdue Pharma Plan to 2nd Circuit
A handful of states and the federal government’s bankruptcy watchdog are seeking to take their appeal of a bankruptcy court’s approval of Purdue Pharma LP’s reorganization plan and settlement of widespread opioid litigation straight to the U.S. Court of Appeals for the Second Circuit, Reuters reported. During a virtual status conference yesterday before U.S. Bankruptcy Judge Robert Drain in White Plains, N.Y., lawyers for the states of Washington, Maryland, Oregon, California, Connecticut and the District of Columbia said they want to expedite their challenge by skipping over a federal district court that would typically hear a bankruptcy appeal. Purdue attorney Marshall Huebner of Davis Polk & Wardwell said during the status conference that he believes they may get a ruling on the merits on Drain's decision faster if they go to the federal district court first, but agreed that the appeals process should move quickly. Purdue filed for bankruptcy in September 2019 to resolve thousands of lawsuits accusing it and the Sackler family members who owned the OxyContin maker of fueling the U.S. opioid crisis through deceptive marketing of its products. The company secured approval on Sept. 1 of its plan and settlement, which include controversial legal protections for the Sacklers. The states and the U.S. Trustee, among others, filed their appeals earlier this month. The challenges will likely focus on the Sackler releases of future opioid litigation, which nine states and the U.S. Trustee opposed. The overall settlement, however, had the support of about 40 states, as well as municipalities, Native American tribes and hospitals, among others.
